Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

in the Cancer Drugs Fund, crizotinib was not a comparator in this appraisal (issue 1, see technical report pages 12 to 14). • The relevant population was the STARTRK-2 subgroup of 78 patients who had: - a confirmed diagnosis of ROS1-positive non-small-cell lung cancer (NSCLC) - measurable disease at baseline - no minimum follow-up restriction - the licensed 600-mg entrectinib dose - no prior ROS1 inhibitor treatment. Analyses based on the STARTRK-2 subgroup were appropriate for decision making (issue 2, see (...) with various gene alterations (n=207) and included 78 people with Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 8 of 16ROS1-positive NSCLC. Most (73%) people had previous therapy for advanced disease and everyone had the licensed entrectinib dose. Data from the STARTRK-2 subgroup (May 2018 enrolment data cut-off) were used

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Lung cancer: NCCP advice for medical professionals on the management of patients undergoing Lung Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic

Alternative RT schedule/Alternative treatment options Level 5 Less than 10 % capacity Individual case discussion Version: 1 Department: NCCP Radiation Oncology Working Group Update date: 05/06/2020 Code: RO_COVID19_12 3 5 Radical Radiotherapy/SABR (Non-metastatic NSCLC & Limited Stage SCLC) Non-Small Cell Lung Cancer (NSCLC) Stage/clinical scenario Potential selection criteria Treatment recommendations T1-T2 (selected T3), N0, M0 – eligible for SABR Small tumour and slow growing disease (documented slow (...) but eligible for radical radiotherapy Small tumour and slow growing disease (documented slow growth of previous imaging or pure lepidic adenocarcinoma on biopsy & imaging) Delay (taking into account capacity, risk/benefit to patient) or standard T1-T2 (selected T3) N0, M0 – non- eligible for SABR but eligible for radical radiotherapy Large tumour and/or tumour with documented progression on previous serial imaging and/or pathological subtype other than pure lepidic adenocarcinoma Standard Locally advanced

2020 Health Service Executive (Ireland) - Clinical Guidelines

3. Selpercatinib (Retevmo) - lung and thyroid cancers

Selpercatinib (Retevmo) - lung and thyroid cancers Drug Approval Package: RETEVMO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RETEVMO Company: Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Application Number: 213246 Approval Date: 05/08/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

4. Lung Cancer Screening with Low-Dose CT: a Meta-Analysis

Lung Cancer Screening with Low-Dose CT: a Meta-Analysis Lung Cancer Screening with Low-Dose CT: a Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Gen Intern Med Actions . 2020 Jun 24. doi: 10.1007/s11606-020-05951-7. Online ahead of print. Lung Cancer Screening with Low-Dose CT: a Meta-Analysis , , , Affiliations Expand Affiliations 1 University of Iowa Carver College of Medicine, Iowa City, IA, USA. richard-m-hoffman@uiowa.edu. 2 Holden Comprehensive Cancer

2020 EvidenceUpdates

5. Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

treatment ? any tumour treatment until disease progression and discontinuation of the study medication ? denosumab c Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lung cancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 11 - Table 7: Characteristics of the intervention – RCT, direct comparison: atezolizumab + carboplatin + etoposide versus placebo + carboplatin + etoposide(multipage table) Study Intervention Comparison a. Treatment could (...) of the best supportive care (BSC) during the maintenance phase. Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lung cancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 12 - Treatment was performed until disease progression, unacceptable toxicity, start of another tumour therapy, withdrawal of consent or death; administration of atezolizumab could be continued beyond progression at the investigator’s discretion if clinical benefit continued

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

2020 EvidenceUpdates

7. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

need and comparator There is an unmet need for treatment options in this disease There is an unmet need for treatment options in this disease 3.1 A patient expert highlighted that people diagnosed with extensive-stage small- cell lung cancer (ES-SCLC) are often dismayed at their lack of treatment options, particularly compared with non-small-cell lung cancer (NSCLC). Treatment options have not changed for decades, and patients are aware of the success of immunotherapy for treating other cancers (...) concluded that the company's time-to-death approach to estimate utilities was acceptable for this particular appraisal, given the specific circumstances, but this should not be considered the usual methodology for this disease. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 17The duration of treatment benefit

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)

Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 30 June 2020 www.nice.org.uk/guidance/ta635 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Ramucirumab (...) with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of ramucirumab with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer because Eli Lilly and Company Limited did

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

9. Lurbinectedin (Zepzelca) - To treat metastatic small cell lung cancer

Lurbinectedin (Zepzelca) - To treat metastatic small cell lung cancer Drug Approval Package: ZEPZELCA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPZELCA Company: Pharma Mar USA, Inc. Application Number: 213702 Approval Date: 06/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

10. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy. PMID: 32150489 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report (...) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

11. Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer

Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

12. Archimedes for biopsy of suspected lung cancer

navigation systems. Archimedes for biopsy of suspected lung cancer (MIB211) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 10Current care pathway Current care pathway People with known or suspected lung cancer should be offered a contrast-enhanced chest CT scan to diagnosis and stage the disease. They should also be offered endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for biopsy (...) of paratracheal and peri-bronchial intra- parenchymal lung lesions. When taking samples, the healthcare professional should ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers. The following publications have been identified as relevant to this care pathway: • NICE's guideline on lung cancer: diagnosis and management • NICE's quality standard on lung cancer in adults • NICE's interventional

2020 National Institute for Health and Clinical Excellence - Advice

13. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

2020 EvidenceUpdates

14. Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. (Abstract)

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced (...) of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment.Among patients

2020 NEJM

15. eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment (...) cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001

2020 European Society for Medical Oncology

16. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lung cancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Evidence Report for Investigating symptoms of lung cancer: a guide for all health professionals

, which can hinder early diagnosis and treatment. 4, 5 Lung cancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lung cancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lung cancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lung cancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lung cancer • adults with rare lung tumours • adults with benign lung tumours, and • adults being screened for lung cancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lung cancer screening

2020 Cancer Australia

18. Investigating symptoms of lung cancer: a guide for all health professionals

The association of lung cancer with smoking can lead to lung cancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lung cancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lung cancer - chronic lung disease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lung cancer, head and neck cancer, bladder cancer Symptoms and signs of lung cancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lung cancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5

2020 Cancer Australia

19. Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer

and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials April 2019, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to May 16, 2019 Search Strategy: # Searches 1 exp lung neoplasms/ or exp lung cancer/ 2 (((lung or thorax or thoracic or pulmonary) adj3 (cancer$ or neoplasm$ or carcinom$ or malignan$ or tumo?r$ or adenocarcinoma$)) or NSCLC).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, ui, sy, sh, tx, ct] 3 1 or 2 4 exp (...) , P.M. Ellis, R. Goffin, W. Hanna, D. Maziak, A. Swaminath, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: April 27, 2020 This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The recommendations were also endorsed

2020 Cancer Care Ontario

20. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report

screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer. INTERPRETATION: There was consensus that during the COVID-19 pandemic, it is appro- priatetodeferenrollmentinlungcancerscreeningandmodifytheevaluationoflungnodules ABBREVIATIONS: CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 19; Lung-RADS = Lung CT Screening Reporting and Data System; pCA = probability (...) : consensus statement; COVID-19; lung cancer screening; lung nodule In some parts of the world, the coronavirus disease 2019 (COVID-19) pandemic has stressed the health- care systems close to or even past their breaking point. Rightfully, much of the attention to date has focused on the immediate needs of patients suffering from the disease, particularly those who are critically ill. The strain on health-care systems and the need to control the virus using containment (testing and isolating cases

2020 American College of Chest Physicians